ATE386520T1 - Kombination von riluzol und levodopa zur behandlung von morbus parkinson - Google Patents

Kombination von riluzol und levodopa zur behandlung von morbus parkinson

Info

Publication number
ATE386520T1
ATE386520T1 AT99915809T AT99915809T ATE386520T1 AT E386520 T1 ATE386520 T1 AT E386520T1 AT 99915809 T AT99915809 T AT 99915809T AT 99915809 T AT99915809 T AT 99915809T AT E386520 T1 ATE386520 T1 AT E386520T1
Authority
AT
Austria
Prior art keywords
combination
riluzole
levodopa
disease
parkinson
Prior art date
Application number
AT99915809T
Other languages
English (en)
Inventor
Veronique Blanchard-Bregeon
Assunta Imperato
Saliha Moussaoui
Marie-Carmen Obinu
Michel Reibaud
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE386520T1 publication Critical patent/ATE386520T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
AT99915809T 1998-04-24 1999-04-22 Kombination von riluzol und levodopa zur behandlung von morbus parkinson ATE386520T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9805153A FR2777781B1 (fr) 1998-04-24 1998-04-24 Associations riluzole et l-dopa pour le traitement de la maladie de parkinson

Publications (1)

Publication Number Publication Date
ATE386520T1 true ATE386520T1 (de) 2008-03-15

Family

ID=9525640

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99915809T ATE386520T1 (de) 1998-04-24 1999-04-22 Kombination von riluzol und levodopa zur behandlung von morbus parkinson

Country Status (22)

Country Link
US (1) US6387936B1 (de)
EP (1) EP1071422B1 (de)
JP (1) JP2002512963A (de)
KR (1) KR100597170B1 (de)
AT (1) ATE386520T1 (de)
AU (1) AU768069B2 (de)
CA (1) CA2329636C (de)
CY (1) CY1110448T1 (de)
CZ (1) CZ300825B6 (de)
DE (1) DE69938179T2 (de)
DK (1) DK1071422T3 (de)
ES (1) ES2300141T3 (de)
FR (1) FR2777781B1 (de)
HU (1) HU228902B1 (de)
IL (1) IL139164A (de)
NO (1) NO329032B1 (de)
PT (1) PT1071422E (de)
RU (1) RU2225204C2 (de)
SK (1) SK285531B6 (de)
UA (1) UA70319C2 (de)
WO (1) WO1999055336A1 (de)
ZA (1) ZA200005758B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
EP1746985A4 (de) * 2004-05-21 2010-08-11 Univ Duke Verfahren zur erhöhung der wirkung von serotonin-wiederaufnahmehemmern
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
PL1817006T3 (pl) * 2004-11-07 2013-03-29 F Timothy Guilford Liposomalny preparat do doustnego podawania glutationu (zredukowanego)
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2363124B1 (de) * 2006-06-28 2016-02-17 Lundbeck NA Ltd Pharmazeutische Zusammensetzungen enthaltend Droxidopa
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AU2008226541B2 (en) * 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
EP2514417A3 (de) * 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa und pharmazeutische Zusammensetzung davon, zur Behandlung von Stimmungsstörungen, Schlafstörungen oder Aufmerksamkeitsdefizit-Störungen
MX2010014222A (es) * 2008-06-30 2011-03-29 Novartis Ag Star Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.
US20100160295A1 (en) * 2008-11-06 2010-06-24 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders
EP2228054A1 (de) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Wässrige Riluzol-Suspensionen
EP2629615B1 (de) 2010-10-22 2018-10-10 Duke University Retardformulierungen aus 5-hydroxytryptophan als zusatz für pro-serotonergische therapien
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма

Also Published As

Publication number Publication date
DE69938179T2 (de) 2009-02-12
US6387936B1 (en) 2002-05-14
CZ20003908A3 (cs) 2001-02-14
ZA200005758B (en) 2002-01-17
PT1071422E (pt) 2008-05-05
JP2002512963A (ja) 2002-05-08
SK285531B6 (sk) 2007-03-01
CA2329636C (fr) 2009-09-08
CA2329636A1 (fr) 1999-11-04
FR2777781A1 (fr) 1999-10-29
NO20005290D0 (no) 2000-10-20
NO20005290L (no) 2000-10-20
CY1110448T1 (el) 2015-04-29
IL139164A0 (en) 2001-11-25
AU3425599A (en) 1999-11-16
DE69938179D1 (de) 2008-04-03
KR100597170B1 (ko) 2006-07-05
NO329032B1 (no) 2010-08-02
WO1999055336A1 (fr) 1999-11-04
RU2225204C2 (ru) 2004-03-10
KR20010042960A (ko) 2001-05-25
DK1071422T3 (da) 2008-06-16
SK15882000A3 (sk) 2001-04-09
HUP0101645A2 (hu) 2001-09-28
EP1071422A1 (de) 2001-01-31
HUP0101645A3 (en) 2002-10-28
AU768069B2 (en) 2003-12-04
ES2300141T3 (es) 2008-06-01
FR2777781B1 (fr) 2004-04-09
UA70319C2 (en) 2004-10-15
EP1071422B1 (de) 2008-02-20
HU228902B1 (en) 2013-06-28
IL139164A (en) 2005-12-18
CZ300825B6 (cs) 2009-08-19

Similar Documents

Publication Publication Date Title
DE69938179D1 (de) Kombination von riluzol und levodopa zur behandlung von morbus parkinson
GB0108592D0 (en) Therapeutic agents
ATE385794T1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
DE69829921D1 (de) Vorrichtung zur Behandlung von Körpergewebe
BG106450A (en) Use of retigabin for treating neuropathic pain
DE59607691D1 (de) Anordnung zur elektro-thermischen behandlung des menschlichen oder tierischen körpers
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
GB0223040D0 (en) Therapeutic compounds
PL310475A1 (en) Application of anticonvulsants in treating neuro-aids diseases
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
DE69924379D1 (de) Verbindungen und zubereitungen zur behandlung der ischämie des gewebes
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
DE69840432D1 (de) Arzneimittel zur behandlung der augen
ATE218866T1 (de) Kombinationstherapie zur behandlung von aids
FI952953A7 (fi) Aineita metabolisten luustosairauksien hoitamiseen
DE69214647D1 (de) Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz
ATE323486T1 (de) Verwendung des riluzols oder dessen salzen zur phophylaxe und behandlung der adrenoleukodystrophie
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
RU97111440A (ru) Препарат для лечения отморожений
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
DE69822628D1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1071422

Country of ref document: EP